Why carry out this study?

Drug survival studies of dupilumab show that many patients continue treatment through 1 year, suggesting that patients that do not achieve an optimal response during short-term treatment experience clinically relevant benefits over time. This analysis was conducted specifically to assess long-term (100-week) response in patients who did not initially achieve the pre-specified clinical trial endpoints.

What was learned from the study?

The study showed that long-term (100-week) treatment with dupilumab is associated with improvement in AD in most patients with suboptimal responses at 16 weeks. Regardless of the dosing option (qw or q2w) in the parent study, most patients achieved clinically relevant benefits.